News & Events

Cytovia Therapeutics R&D Team Presents Poster at ASGCT 2023 on GPC3-Targeted TALEN® Gene-Edited CAR-iNK Cell

May 17th, 2023

Cytovia Therapeutics R&D Team Presents 2 Posters at AACR 2023 on GPC3-Targeted Bispecific Antibody & TALEN® Gene-Edited iNK Cells

April 17th, 2023

Cytovia Therapeutics R&D Leadership Presents Updated Data at Innate Killer Summit in San Diego

March 31st, 2023

Cytovia Therapeutics R&D Team Publishes Preclinical Data for GPC3-Targeted Bispecific Antibody in Cells

March 24th, 2023

Cytovia Therapeutics Presents New Data on CD38-Targeted Flex-NK™ Bispecific Antibody at 2022 American Society of Hematology Annual Meeting

December 9th, 2022

Cytovia Therapeutics Presents New Data on TALEN® Gene-Edited iNK Cells and GPC3-Targeted Flex-NK™ Bispecific Antibodies at 2022 SITC Annual Meeting

November 7th, 2022

The Next Wave: Going Beyond CAR-T Cells with Cell-Based Therapies (Q&A ft. CEO Dr. Daniel Teper - Drug Target Review)

November 3rd, 2022

Cytovia Therapeutics To Present New Data on CD38 Flex-NK™ Cell Engager Bispecific Antibodies for Multiple Myeloma at 2022 ASH Annual Meeting

October 27th, 2022

Cytovia Therapeutics To Present New Data on TALEN® Gene-Edited iNK Cells and GPC3-Targeted Flex-NK™ Cell Engagers at 2022 SITC Annual Meeting

October 6th, 2022

Watch Cytovia CEO Dr. Daniel Teper's Presentation at the Recent Jefferies Cell & Genetic Medicine Summit in New York City

October 3rd, 2022

The Onco'Zine Brief: ESMO 2022: Advances in the Treatment of Cancer (featuring Cytovia CEO Dr. Daniel Teper)

October 1st, 2022

Cytovia Therapeutics Presents New Preclinical Data for Its GPC3 Flex-NK™ Cell Engager Antibody in Combination With Natural Killer Cells at ESMO 2022 in Paris

September 12th, 2022

Cytovia Therapeutics Mourns the Passing of Cancer Immunotherapy Industry Leader and COO Dr. Olivier Jean-Marie Gouédard

September 7th, 2022

The Power of Combining iPSC-derived NK Cell Therapy & NK-Cell Engager Antibodies (Cell & Gene Therapy Insights)

August 1st, 2022

Cytovia Therapeutics - Natural Killer Cells to Fight Cancer (Health Professional Radio)

July 13th, 2022

Isleworth and Cytovia Terminate Merger Agreement

June 30th, 2022

Cytovia Therapeutics Presents Antitumor Activity of its CD38-Targeting Flex-NK™ Cell Engager Antibody at EHA 2022 Congress

June 10th, 2022

IPSCs For Democratized Cell Therapy (BioProcess Online)

June 7th, 2022

CYT-338 Shows Anticancer Activity in Preclinical Tests (Myeloma Research News)

June 6th, 2022

Producing Natural Killer Immune Cells from Induced Pluripotent Stem Cells to Treat Cancer with Daniel Teper Cytovia Therapeutics (Empowered Patient Podcast)

May 31st, 2022

Embracing the Promise of Natural Killer Cells in the Fight Against Cancer (The Bio Report Podcast)

May 19th, 2022

Cytovia Therapeutics to Present In Vivo Multiple Myeloma Data of its CD38-Targeting Flex-NK™ Cell Engager at EHA 2022 Congress

May 19th, 2022

Cytovia Therapeutics to Present at AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer

May 6th, 2022

Cytovia Enters Into Business Combination Agreement With Isleworth Healthcare Acquisition Corp.

April 26th, 2022

Cytovia is Empowering NK Cells and NK Engager Antibodies Against Cancer (BioSpace)

April 12th, 2022

Cytovia Therapeutics Reports Preclinical Activity of its iNK Cells and Flex-NK™ Cell Engagers at the 2022 AACR Annual Meeting

April 8th, 2022

Cytovia Therapeutics’ Leadership to Present at Upcoming Conferences

March 29th, 2022

Cytovia to Present Preclinical Data for iNK Cells and Flex-NK™ Cell Engager Antibodies at 2022 AACR Annual Meeting

March 16th, 2022

Cytovia Therapeutics’ Scientific Leadership to Present at Upcoming Conferences

December 8th, 2021

Cytovia and Cellectis Expand Their TALEN Gene-Edited iNK Partnership
to Enable Broader Collaboration in China

November 18th, 2021

Cytovia Therapeutics and its Newly Formed China-Focused CytoLynx Joint Venture Raise $45 Million to Advance NK Cell Therapy Pipeline

September 13th, 2021

Watch a replay of Cytovia's presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, featuring CEO Daniel Teper and CMO Stanley Frankel

September 13th, 2021

Olivier Gouédard, PharmD, MBA joins Cytovia Therapeutics as Chief Operating Officer

June 22nd, 2021

Watch a replay of CEO Dr. Daniel Teper & CMO Dr. Stanley Frankel's presentation at the Jeffries Virtual Healthcare Conference

June 1st, 2021

Cytovia Therapeutics CEO Dr. Daniel Teper to Present at Two Upcoming Conferences

May 14th, 2021

Cytovia Therapeutics Expands Leadership Team

May 13th, 2021

Stanley R. Frankel, MD FACP joins Cytovia Therapeutics as Chief Medical Officer

April 28th, 2021

Cytovia Therapeutics Files New Patents for its NK Cell Engager Multifunctional Antibodies (FLEX-NK®)

April 12th, 2021

Watch the "Pushing the Envelope on Bispecific Antibodies" Panel at the 33rd Annual ROTH Conference, Featuring Cytovia CEO Dr. Daniel Teper

March 18th, 2021

Cytovia Therapeutics Opens Boston R&D Center of Excellence and Announces cGMP Manufacturing Facility, Aiming to Start Clinical Trials for its Gene-Edited iPSC CAR-NK Cells by 2022

March 17th, 2021

Watch a replay of Cytovia CEO Daniel Teper's presentation at the H.C. Wainwright Global Life Sciences Conference

March 16th, 2021

Cytovia Therapeutics’ Management to Present at Three Upcoming Conferences in March

March 8th, 2021

Cytovia Therapeutics and Cellectis Partner to Develop TALEN® Gene-Edited iPSC-Derived Natural Killer Cells

February 16th, 2021

Cytovia Therapeutics Partners with National Cancer Institute to Develop Novel Gene-Edited, iPSC-Derived GPC3 CAR NK Cells for the Treatment of Solid Tumors

January 13th, 2021

Watch a replay of the Cell Therapy panel at the 10th Annual LifeSci Partners Corporate Access Event, featuring Cytovia CEO Dr. Daniel Teper

January 7th, 2021

Watch a replay of Cytovia's recent fireside chat at the RBC Capital Markets Healthcare Conference, featuring CEO Dr. Daniel Teper and CSO Dr. Wei Li

December 16th, 2020

Cytovia Therapeutics announces plans to initiate in 2021 Clinical Development of Universal iPSC NK Cell Therapy for Hematological and Solid Tumors

December 8th, 2020

Cytovia Therapeutics to Present at Jefferies Virtual London Healthcare Conference

November 12th, 2020

Cytovia Therapeutics partners with INSERM to develop selective CD38 NK therapeutics and offer new treatment options for Multiple Myeloma patients

October 8th, 2020

Watch Cytovia's recent webinar at the Jefferies Cell Therapy Virtual Summit, featuring CEO Dr. Daniel Teper and CSO Dr. Wei Li

October 7th, 2020

Cytovia Therapeutics to present at Jefferies Cell Therapy Virtual Summit, BIO Investor Forum and New York Stem Cell Foundation Conference in October 2020

September 29th, 2020

Cytovia Therapeutics and NYSCF Announce Filing of Provisional Patent for iPSC-Derived NK Cells to Produce Unlimited On-Demand NK and CAR-NK Cells for the Treatment of Cancer

August 25th, 2020

Cytovia Therapeutics Licenses Productivity-Boosting Manufacturing Technology for Its NK Engager Multifunctional Antibodies From ProteoNic

August 12th, 2020

Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics’ First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of Glioblastoma & Other Solid Tumors

August 3rd, 2020

Cytovia Therapeutics, Inc Adds Two Industry Leaders to Its Board of Directors

June 24th, 2020

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer

June 3rd, 2020

Cytovia CEO Daniel Teper Featured on MSQ Webinar Series

March 24th, 2020

Hebrew University to Collaborate with Cytovia Therapeutics on Natural Killer Cell Research

March 18th, 2020

Webcast: BIO CEO & Investor Conference

February 12th, 2020

Cytovia CEO Daniel Teper interviewed by Proactive

August 11th, 2020

Cytovia's CAR NK Alliance With NYSCF, UCSF Aims to Overcome Negative Side Effects of CAR T Drugs

February 3rd, 2020

Cytovia Therapeutics and the New York Stem Cell Foundation Research Institute enter into a partnership to develop iPSC derived CAR NK Therapeutics

January 9th, 2020

Cytovia Therapeutics and the University of California, San Francisco enter into a partnership to develop precision gene-edited CAR-NK cell therapy

January 6th, 2020

Cytovia Therapeutics, Inc. and STC Biologics, Inc. enter into a partnership to develop and manufacture NK cell engager multi-specific antibodies

January 2nd, 2020

Cytovia CEO Dr. Daniel Teper to speak at East/West Conference

December 29th, 2019

Cytovia Therapeutics CEO says scientific community 'warming up' to natural killer cell treatments

October 28th, 2019

Cytovia Therapeutics to Present at 2019 Bio Investor Forum

October 21st, 2019

News & Events

Watch a replay of CEO Dr. Daniel Teper & CMO Dr. Stanley Frankel's presentation at the Jeffries Virtual Healthcare Conference

Subscribe Form